Stopped: New evidence warranted a change in the study design and study population group (inclusion/ exclusion criterion). We completed another clinical trial focused on subjects with headache symptoms but this particular clinical trial was terminated.
To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Convergence Insufficiency. It is a Prospective randomized double masked two arm performed on a minimum of 100 to a maximum of 150 subjects identified as symptomatic (CISS questionnaire score equal to or greater than 16) done across 3-10 clinical sites. There are two subgroups: a minimum of 50 in each subgroup(subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects(41-60 years).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Convergence Insufficiency Symptom Score (CISS) questionnaire
Timeframe: 30-40 days